Cognitive Enhancement Treatment for People With Mental Illness Who Do Not Respond to Supported Employment: A Randomized Controlled Trial.

McGurk SR, Mueser KT, Xie H, Welsh J, Kaiser S, Drake RE, et al. Cognitive Enhancement Treatment for People With Mental Illness Who Do Not Respond to Supported Employment: A Randomized Controlled Trial. Am J Psychiatry. 2015;172(9):852-61. DOI: 10.1176/appi.ajp.2015.14030374. PubMed PMID: 25998278.

Adjunctive raloxifene treatment improves attention and memory in men and women with schizophrenia.

Weickert TW, Weinberg D, Lenroot R, Catts SV, Wells R, Vercammen A, et al. Adjunctive raloxifene treatment improves attention and memory in men and women with schizophrenia. Mol Psychiatry. 2015;20(6):685-94. DOI: 10.1038/mp.2015.11. PubMed PMID: 25980345.

Common and distinct neural effects of risperidone and olanzapine during procedural learning in schizophrenia: a randomised longitudinal fMRI study.

Kumari V, Ettinger U, Lee SE, Deuschl C, Anilkumar AP, Schmechtig A, et al. Common and distinct neural effects of risperidone and olanzapine during procedural learning in schizophrenia: a randomised longitudinal fMRI study. Psychopharmacol (berl). 2015;232(17):3135-47. DOI: 10.1007/s00213-015-3959-1. PubMed PMID: 25980483.

IL-6, IL-18, sIL-2R, and TNFα proinflammatory markers in depression and schizophrenia patients who are free of overt inflammation.

Al-Hakeim HK, Al-Rammahi DA, Al-Dujaili AH. IL-6, IL-18, sIL-2R, and TNFα proinflammatory markers in depression and schizophrenia patients who are free of overt inflammation. J Affect Disord. 2015;182:106-14. DOI: 10.1016/j.jad.2015.04.044. PubMed PMID: 25985379.

Leukocyte telomere length in patients with schizophrenia: A meta-analysis.

Polho GB, De-Paula VJ, Cardillo G, Dos Santos B, Kerr DS. Leukocyte telomere length in patients with schizophrenia: A meta-analysis. Schizophr Res. 2015;165(2-3):195-200. DOI: 10.1016/j.schres.2015.04.025. PubMed PMID: 25975826.

Pharmacogenetics of response to antipsychotics in patients with schizophrenia.

Arranz MJ, Rivera M, Munro JC. Pharmacogenetics of response to antipsychotics in patients with schizophrenia. CNS Drugs. 2011;25(11):933-69. DOI: 10.2165/11595380-000000000-00000. PubMed PMID: 22054119.

Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene.

Schäfer M, Rujescu D, Giegling I, Guntermann A, Erfurth A, Bondy B, et al.. Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene. Am J Psychiatry. 2001;158(5):802-4. DOI: 10.1176/appi.ajp.158.5.802. PubMed PMID: 11329406.

Taq1A polymorphism in the dopamine D2 receptor gene as a predictor of clinical response to aripiprazole.

Kwon JS, Kim E, Kang D-H, Choi JS, Yu K-S, Jang I-J, et al. Taq1A polymorphism in the dopamine D2 receptor gene as a predictor of clinical response to aripiprazole. Eur Neuropsychopharmacol. 2008;18(12):897-907. DOI: 10.1016/j.euroneuro.2008.07.010. PubMed PMID: 18786813.

D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis.

Zhang J-P, Lencz T, Malhotra AK. D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis. Am J Psychiatry. 2010;167(7):763-72. DOI: 10.1176/appi.ajp.2009.09040598. PubMed PMID: 20194480.

Tardive dyskinesia and DRD2, DRD3, DRD4, 5-HT2A variants in schizophrenia: an association study with repeated assessment.

Lattuada E, Cavallaro R, Serretti A, Lorenzi C, Smeraldi E. Tardive dyskinesia and DRD2, DRD3, DRD4, 5-HT2A variants in schizophrenia: an association study with repeated assessment. Int J Neuropsychopharmacol. 2004;7(4):489-93. DOI: 10.1017/S1461145704004614. PubMed PMID: 15383158.